The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 17, 2015

Filed:

Mar. 28, 2014
Applicants:

Protiva Biotherapeutics, Inc., Burnaby, CA;

Trustees of Boston University, Boston, MA (US);

United States Army Medical Research and Materiel Command, Frederick, MD (US);

Inventors:

Thomas W. Geisbert, Albany, TX (US);

Amy C. H. Lee, Burnaby, CA;

Marjorie Robbins, Vancouver, CA;

Vandana Sood, Vancouver, CA;

Adam Judge, Vancouver, CA;

Lisa E. Hensley, Frederick, MD (US);

Ian MacLachlan, Mission, CA (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12N 15/113 (2010.01); A61K 9/127 (2006.01); A61K 31/713 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1131 (2013.01); A61K 9/127 (2013.01); A61K 9/1271 (2013.01); A61K 31/713 (2013.01); C12N 2310/14 (2013.01); C12N 2310/321 (2013.01); C12N 2760/14111 (2013.01);
Abstract

The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.


Find Patent Forward Citations

Loading…